Annovis Bio Inc. has reported its financial results for the first quarter of 2025. The company's cash and cash equivalents increased to $22.2 million as of March 31, 2025, from $10.6 million on the same date in 2024. Research and development expenses decreased to $5.0 million for the three months ended March 31, 2025, compared to $6.5 million for the same period in 2024. General and administrative expenses remained steady at $1.3 million for both the first quarters of 2025 and 2024. Annovis reported a net loss per common share of $0.32 for both basic and diluted shares in the first quarter of 2025, compared to a $0.10 basic and $0.72 diluted net loss per share for the same period in 2024. Operationally, Annovis has initiated a pivotal Phase 3 clinical trial in early Alzheimer's disease (AD), which started on February 5, 2025. The trial aims to enroll approximately 760 participants to evaluate the effects of buntanetap or placebo over a dual 6/18-month period. The company also actively participated in significant scientific conferences during February and March 2025, where it presented findings from its ongoing clinical trials and contributed to discussions on advancements in neurodegenerative disease treatments. Additionally, Annovis was granted a U.S. patent in January for methods involving the treatment and prevention of acute brain and nerve injuries using buntanetap.